Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Nordic Pharma, USA | INDUSTRY |
Not provided
Not provided
Not provided
This research study is to see if using Lacrifill is safe, easy to use, and helpful for people who wear contact lenses but can't wear them comfortably for long. Specifically, the study aims to determine whether regular use of Lacrifill over a 2-3 month period can help people wear their contacts longer without discomfort and reduce signs and symptoms of dry eye.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lacrifill | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lacrifill | Drug | Lacrifill is a cross-linked hyaluronic acid derivative that temporarily blocks tear drainage, allowing patients eyed to be bathed in their own natural tears. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Dry eye signs | To asses the effect of Lacrifill. | 2-3 months |
| Dry Eye Symptoms | To asses the effect of Lacrifill. | 2-3 Months |
| Contact Lens Tolerability | To asses the effect of Lacrifill. | 2-3 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate Changes in CLDEQ-8 Questionnaire | To assess the effect of Lacrifill | 2-3 Months |
| Evaluate the Changes in the OSDI Questionnaire | To assess the effect of Lacrifill |
Not provided
Inclusion Criteria
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Patti Myers, COT | Contact | 5707145910 | patti.myers@vipeyes.com | |
| Cheryl Bayley | Contact | 5707145915 |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Eye Care Specialists | Recruiting | Kingston | Pennsylvania | 18704 | United States |
Unique study ID (no direct identifiers)
Demographic characteristics (e.g., age, sex, race/ethnicity)
Baseline clinical characteristics relevant to the study
Outcome data (primary and secondary endpoints)
Adverse events and serious adverse events
Concomitant medications
Intervention/exposure data
Follow-up assessments and visit dates
12-2025 to 08-2026
We will provide source documents with the information.
Not provided
Not provided
| ID | Term |
|---|---|
| D015352 | Dry Eye Syndromes |
| ID | Term |
|---|---|
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 2-3 Months |
| Evaluate changes in Contact Lens Wear Time | To assess the effect of Lacrifill | 2-3 Months |
| Evaluate Clinical Signs of Tear Break Up Time | To assess the effect of Lacrifill | 2-3 Months |
| Evaluate Clinical Signs of Corneal Staining | To assess the effect of Lacrifill | 2-3 Months |
| Evaluate clinical Signs of Schirmer's Tear Test | To assess the effect of Lacrifill | 2-3 Months |